MDGL (Madrigal Pharmaceuticals Inc) Earnings per share for the last four quarters

Madrigal Pharma (MDGL) - corporate logo

Madrigal Pharmaceuticals (MDGL) adheres to sustainability principles by implementing energy-efficient cooling and strict waste control. The rolling change in earnings per share YoY serves as a confidence indicator, where the parameter value equals 54.50. Madrigal Pharmaceuticals (MDGL) is a pioneer in MASH/NASH therapy, leveraging powerful scientific and technical capabilities. Meanwhile, drug production is delegated to external partners through exclusive SLA contracts subject to rigorous auditing.

MDGL madrigalpharma.com Net earnings per share (EPS TTM) (02/11/2024 - 11/18/2026)

MDGL (Madrigal Pharmaceuticals): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:MDGL (Madrigal Pharmaceuticals Inc)
Core merchandise of Madrigal Corp

This metric captures the rolling year earnings per share (EPS) trend, revealing the actual pace of capitalization growth. Analyzing such a trend allows for the separation of random financial spikes from sustainable business expansion. By assessing the rolling annual growth of net income per share, an investor can see Madrigal Pharmaceuticals (MDGL) transitioning to the commercialization stage. For biopharmaceuticals, this signifies the transformation of multi-year R&D expenditures into ultra-high margins for approved drugs.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS